Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Melanoma 82Neoplasms 47Carcinoma, Non-Small-Cell Lung 28Colorectal Neoplasms 20Neoplasm Metastasis 15Multiple Myeloma 14Thyroid Neoplasms 13Glioma 12Pancreatic Neoplasms 11Hematologic Neoplasms 10Thyroid Carcinoma, Anaplastic 9Brain Neoplasms 8Lung Neoplasms 7Triple Negative Breast Neoplasms 5Skin Neoplasms 5Rectal Neoplasms 5Neurofibromatosis 1 5Lymphoma 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Breast Neoplasms 5Astrocytoma 5Thyroid Cancer, Papillary 4Recurrence 4Prostatic Neoplasms 4Neurofibroma, Plexiform 4Glioblastoma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uveal Melanoma 3

Interventions

dabrafenib 4trametinib 3Tetracycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ameloblastoma × trametinib × Clear all
NCT06819605 2025-02-11

NETCAM-RCT

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2/3 Not yet recruiting
46 enrolled

Ameloblastoma

NCT06653517 2024-10-22

NETCAM

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2 Recruiting
12 enrolled

Ameloblastoma

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Stanford University

Phase 2 Completed
1 enrolled 5 charts

Ameloblastoma, Adamantinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡